<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03008642</url>
  </required_header>
  <id_info>
    <org_study_id>PI2016_843_0032</org_study_id>
    <nct_id>NCT03008642</nct_id>
  </id_info>
  <brief_title>CO-Rebreathing in Comparison to Isotopic Red Cell Volume Determination in the Diagnosis of Primitive and Secondary Polycythemia</brief_title>
  <acronym>Poly-CO</acronym>
  <official_title>CO-Rebreathing in Comparison to Isotopic Red Cell Volume Determination in the Diagnosis of Primitive and Secondary Polycythemia: a Multicentric Study. Co-Rebreathing for the Measurement of Total Red Cell Mass in Polycythemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimized CO-Rebreathing is an efficient method to evaluate the red cell mass and has&#xD;
      been used in the vast majority of studies in sport medicine. However, this method has never&#xD;
      been evaluated on a large scale in the diagnosis of primitive or secondary polycythemia. The&#xD;
      standard procedure to evaluate the red cell mass is based on isotopic measurement using&#xD;
      Cr51-labelled red cells, but its lack of availability in many centers highlights the need for&#xD;
      a non-invasive and rapid alternative method. The purpose of this study is to evaluate and&#xD;
      validate the CO-Rebreathing method in this set of indications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The definition of a true polycythemia is stricto sensu an increased red cell mass (RCM) above&#xD;
      125% of the expected value depending on the size and the weight of the patient. However, this&#xD;
      measurement requires an isotopic labeling of red cells and is not available in most of the&#xD;
      hospitals. Therefore, the diagnosis of polycythemia, and particularly Polycythemia Vera (PV)&#xD;
      is based on routine red blood cells parameters, i.e. hemoglobin level and hematocrit. If&#xD;
      these parameters are efficient in marked polycythemia, discrepancies have been observed in&#xD;
      milder cases. Two situations where a RCM evaluation is particularly required can be&#xD;
      described:&#xD;
&#xD;
        -  In patients with a hematocrit level between 52 and 60% (men) or between 48 and 56%&#xD;
           (women) in order to limit invasive investigations to patients with a confirmed&#xD;
           polycythemia diagnosis&#xD;
&#xD;
        -  In JAK2V617F positive myeloproliferative neoplasms (MPN) with hematocrit and hemoglobin&#xD;
           levels under the PV cut-off in order to discriminate between masked PV and essential&#xD;
           thrombocythemia CO-Rebreathing is a fast, non invasive alternative method for RCM&#xD;
           evaluation. It is based on the high affinity of carbon monoxide (CO) for hemoglobin. The&#xD;
           decrease in the HbCO percentage after CO inhalation is dependent on the total hemoglobin&#xD;
           mass from which RCM can be obtained. The investigators propose a tri-centric study&#xD;
           evaluating CO-Rebreathing as an alternative tool to measure RCM in the diagnosis of&#xD;
           polycythemia in the two categories of patients described above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>equivalence of RCM determination by CO-Rebreathing in comparison to the traditional isotopic measurement in the diagnosis of polycythemia</measure>
    <time_frame>1 month</time_frame>
    <description>The primary outcome is to prove the equivalence of RCM determination by CO-Rebreathing in comparison to the traditional isotopic measurement in the diagnosis of polycythemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE / SAE / EI</measure>
    <time_frame>1 month</time_frame>
    <description>Incidence, grade type according to NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of thrombotic and hemorrhagic complications</measure>
    <time_frame>1 month</time_frame>
    <description>Cumulative incidence of thrombotic and hemorrhagic complications List according to PT1 protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deaths and causes</measure>
    <time_frame>1 month</time_frame>
    <description>Deaths and causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the results of VGTCO and VGTi</measure>
    <time_frame>1 month</time_frame>
    <description>Analysis of the results of VGTCO and VGTi as a function of hemoglobin and hematocrit</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Polycythemia</condition>
  <arm_group>
    <arm_group_label>CO-Rebreathing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CO-Rebreathing technique at diagnosis of polycythemia</intervention_name>
    <description>The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.</description>
    <arm_group_label>CO-Rebreathing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patient&#xD;
&#xD;
          2. Informed consent obtained&#xD;
&#xD;
          3. Requirement of an isotopic red cell mass determination:&#xD;
&#xD;
             a - Hematocrit between 52 and 60% (men) or 48 and 56% (women) with no argument for a&#xD;
             PV (JAK2V617F negative, EPO level normal/high).&#xD;
&#xD;
             b - Patients with a JAK2V617F positive MPN and a hematocrit level between 46 and 50%&#xD;
             (women) or 48 and 52% for men.&#xD;
&#xD;
          4. No recent vascular event (&lt;6 mois)&#xD;
&#xD;
          5. No unstable coronaropathy&#xD;
&#xD;
          6. Non smoking since 24 hours.&#xD;
&#xD;
          7. ECOG &lt;2&#xD;
&#xD;
          8. Negativity of pregnancy test/effective contraception for childbearing age women,&#xD;
&#xD;
          9. Health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recent venous event &lt;1 months, cerebral stroke &lt; 6 mois)&#xD;
&#xD;
          2. Evolutive cardiopathy (&lt; 6 months)&#xD;
&#xD;
          3. Chronic Respiratory failure&#xD;
&#xD;
          4. Smokers with no withdrawal in the last 24 hours before CO-Rebreathing&#xD;
&#xD;
          5. Basal HbCO&gt;7% the day of CO-Rebreathing&#xD;
&#xD;
          6. Pregnant or breast feeding women&#xD;
&#xD;
          7. Patient enable to give an informed consent&#xD;
&#xD;
          8. Inclusion in an interventional clinical trial in the last three months.&#xD;
&#xD;
          9. Any contraindication to lung function testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loïc GARCON, professor</last_name>
    <role>Study Director</role>
    <affiliation>CHU Amiens-Picardie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lydia ROY, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Henri Mondor, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marjolaine GEORGES, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Dijon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Loïc GARCON, professor</last_name>
    <phone>+33 322 087 056</phone>
    <email>garcon.loic@chu-amiens.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed AIT AMER MEZIANE, Phd</last_name>
    <phone>+33 322 088 384</phone>
    <email>aitamermeziane.mohamed@chu-amiens.fr</email>
  </overall_contact_backup>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycythemia</keyword>
  <keyword>CO-Rebreathing</keyword>
  <keyword>red cell mass determination</keyword>
  <keyword>myeloproliferative neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

